Cover Image
市場調查報告書

全球泌尿道感染(UTI)治療藥市場 - 成長,趨勢,預測(2017年∼2022年)

Global Urinary Tract Infection Therapeutics Market - Segmented by Type of Drug, and Indication - Growth, Trends and Forecasts (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 391459
出版日期 內容資訊 英文 117 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球泌尿道感染(UTI)治療藥市場 - 成長,趨勢,預測(2017年∼2022年) Global Urinary Tract Infection Therapeutics Market - Segmented by Type of Drug, and Indication - Growth, Trends and Forecasts (2018 - 2023)
出版日期: 2018年02月08日 內容資訊: 英文 117 Pages
簡介

美國女性的5人有1人罹患泌尿道感染(UTI)。還有2002年中,起因於泌尿道感染的住院數量報告是150萬件。

本報告提供全球泌尿道感染(UTI)治療藥市場相關調查,市場概要,各治療類型、症狀、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素以及市場機會分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 調查的成果
  • 市場定義
  • 調查對象期間及預測
  • 一般調查的前提條件
  • 報告概要

第2章 調查方法

  • 簡介
  • 分析方法
  • 調查的時間軸
  • 調查的階段
    • 2次調查
    • 討論指南
    • 市場工程&計量經濟學模式

第3章 摘要整理

第4章 主要推論

第5章 市場及產業的趨勢

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 市場動態

  • 市場成長要素
    • 發病率高和診斷的正確性
    • 複合治療藥
    • 成藥的適應症
  • 市場阻礙因素
    • 低價格的學名藥的競爭激烈化
  • 市場機會
  • 主要課題

第7章 全球泌尿道感染(UTI)治療藥市場

  • 各治療藥類型
    • 青霉素 & 複合治療藥
    • 奎諾酮類抗生素(Quinolones)類
    • 頭孢菌素
    • Aminoglycosides抗體
    • 磺胺類藥物
    • Azoles & Amphotericin B
    • 四環黴素
    • 硝基餡餅
    • 其他
  • 各症狀
    • 複雜性UTI
    • 復發性複雜性UTI
    • 非複雜性UTI
    • 神經原因性膀胱

第8章 全球泌尿道感染(UTI)治療藥市場:各地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英語
    • 法國
    • 義大利
    • 西班牙、葡萄牙
    • 斯堪地那維亞各國
    • 荷比盧三國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲、紐西蘭
    • 韓國
    • 其他
  • 中東、非洲
    • 波灣合作理事會(GCC)
    • 南非
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他

第9章 競爭情形

  • M&A分析
  • 新產品的銷售
  • 協定,合作,夥伴關係

第10章 企業簡介

  • Pfizer
  • Boehringer Ingelheim
  • Bayer
  • GlaxoSmithKline
  • Novartis
  • Hoffman-La Roche
  • Johnson & Johnson
  • AstraZeneca
  • Cipla
  • Cubist Pharmaceuticals
  • Osel Inc
  • Novexel
  • MerLion Pharmaceuticals
  • 其他

第11章 分析師的投資機會預測

第12章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 33114

The global urinary tract infection therapeutics market is expected to register a CAGR of 3.5% during the forecast period 2018 to 2023. North America dominates the market due to high Urinary Tract Infection (UTI) detection along with increasing diabetes prevalence in the region.

Increasing Prevalence of Diabetes and Kidney Stones

According to World Health Organization (WHO), in 1980 there were 108 million people suffering from diabetes, this number increased to 422 million in 2014. While the prevalence of diabetes in adults increased from 4.7% in 1980 to 8.5% in 2014. This trend of increment in diabetes prevalence rate among adults is expected to continue in the forecast period. Therefore with increasing prevalence, the number of UTI increases, and with increase in UTI, the demand for drugs increases. Thus increasing prevalence of diabetes worldwide is expected to act as a major driver for the global urinary tract infection therapeutics market.

In addition, launch of combination drugs which are more effective and increasing geriatric population are also expected to boost the growth of urinary tract infection therapeutics market.

Adverse Effects Associated with the Use of Medication

According to Centers for Education & Research on Therapeutics, over 2 million cases of Adverse Drug Reactions (ADRs) are reported every year, out of which there are approximately 100,000 deaths. According to FDA, it is also estimated that each year over 350,000 ADRs occur in U.S nursing homes alone. With such increasing cases of ADRs being reported in every corner of the globe, there is averseness among population for the adoption of drugs, which is acting as a major restraint for the urinary tract infection therapeutics market.

Additionally, lack of awareness about the prevalence of UTI in developing and underdeveloped nations is restraining the growth of the market.

North America to Dominate the Market

The Urinary Tract Infection Therapeutics market is segmented by Drug type, Indication type and geography. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America.

North America dominates the urinary tract infection therapeutics market due to high UTI detection along with increasing diabetes prevalence in the region. Europe is also expected to boost the UTI therapeutics market owing to increased accessibility to healthcare facilities along with high UTI prevalence among the population.

Key Developments in the Market

August 2017: FDA approved Vabomere for adults. Vabomere is an antibacterial drug which is used for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis (a type of kidney infection caused by specific bacteria). Vabomere contains meropenem and vaborbactam.

December 2017: F.D.A has accepted for review of NDA (New Drug Application) submitted by Achaogen for plazomicin to treat cUTI including pyelonephritis and bloodstream infections (BSI), and has set a target action date under Prescription Drug User Fee Act (PDUFA) on june, 2018.

Key players: PFIZER LIMITED, BOEHRINGER INGELHEIM, BAYER AG, GLAXOSMITHKLINE PLC, NOVARTIS AG, F. HOFFMANN-LA ROCHE LTD, JOHNSON & JOHNSON, ASTRAZENECA, CIPLA INC and MERLION PHARMA.

Reasons to Purchase this Report

Market analysis for the Global Urinary Tract Infection Therapeutics Market, with region-specific assessments and competition analysis on a global and regional scale.

Analyzing various perspectives of the industry with the help of Porter's five forces analysis

The treatment type that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares and strategies employed by the major market players.

3 months analyst support along with the Market Estimate sheet in excel.

Customization of the Report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1. INTRODUCTION

  • 1.1 MARKET DEFINITION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. KEY INFERENCES

5. MARKET OVERVIEW

  • 5.1 CURRENT MARKET SCENARIO
  • 5.2 PORTER'S FIVE FORCES ANALYSIS
    • 5.2.1 BARGAINING POWER OF SUPPLIERS
    • 5.2.2 BARGAINING POWER OF CONSUMERS
    • 5.2.3 THREATS OF NEW ENTRANTS
    • 5.2.4 THREAT OF SUBSTITUTE PRODUCT AND SERVICES
    • 5.2.5 COMPETITIVE RIVALRY WITHIN THE INDUSTRY

6. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)

  • 6.1 MARKET DRIVERS
    • 6.1.1 INCREASING PREVALENCE OF DIABETES AND KIDNEY STONES
    • 6.1.2 LAUNCH OF COMBINATION DRUGS
    • 6.1.3 INCREASING GERIATRIC POPULATION
  • 6.2 MARKET RESTRAINTS
    • 6.2.1 ADVERSE EFFECTS ASSOCIATED WITH THE USE OF MEDICATION
    • 6.2.2 LACK OF AWARENESS IN DEVELOPING AND UNDERDEVELOPED NATIONS
  • 6.3 OPPORTUNITIES
  • 6.4 KEY CHALLENGES

7. MARKET SEGMENTATION

  • 7.1 SEGMENTATION-BY DRUG TYPE
    • 7.1.1 PENICILLIN & COMBINATIONS
    • 7.1.2 QUINOLONES
    • 7.1.3 CEPHALOSPORIN
    • 7.1.4 AMINOGLYCOSIDE ANTIBODIES
    • 7.1.5 SULPHONAMIDES
    • 7.1.6 AZOLES & AMPHOTERICIN B
    • 7.1.7 TETRACYCLINE
    • 7.1.8 NITROFURANS
    • 7.1.9 OTHERS
  • 7.2 SEGMENTATION-BY INDICATION TYPE
    • 7.2.1 COMPLICATED UTI
    • 7.2.2 RECURRING COMPLICATED UTI
    • 7.2.3 UNCOMPLICATED UTI
    • 7.2.4 NEUROGENIC BLADDER INFECTION
  • 7.3 SEGMENTATION-BY GEOGRAPHY
    • 7.3.1 NORTH AMERICA
      • 7.3.1.1 UNITED STATES
      • 7.3.1.2 CANADA
      • 7.3.1.3 MEXICO
    • 7.3.2 EUROPE
      • 7.3.2.1 FRANCE
      • 7.3.2.2 GERMANY
      • 7.3.2.3 UNITED KINGDOM
      • 7.3.2.4 ITALY
      • 7.3.2.5 SPAIN
      • 7.3.2.6 REST OF EUROPE
    • 7.3.3 ASIA-PACIFIC
      • 7.3.3.1 CHINA
      • 7.3.3.2 JAPAN
      • 7.3.3.3 INDIA
      • 7.3.3.4 AUSTRALIA & NEW ZEALAND
      • 7.3.3.5 SOUTH KOREA
      • 7.3.3.6 REST OF ASIA-PACIFIC
    • 7.3.4 MIDDLE EAST & AFRICA
      • 7.3.4.1 GCC
      • 7.3.4.2 SOUTH AFRICA
      • 7.3.4.3 REST OF THE MIDDLE EAST & AFRICA
    • 7.3.5 SOUTH AMERICA
      • 7.3.5.1 BRAZIL
      • 7.3.5.2 ARGENTINA
      • 7.3.5.3 REST OF SOUTH AMERICA

8. COMPETITIVE LANDSCAPE

  • 8.1 MERGERS & ACQUISITION ANALYSIS
  • 8.2 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
  • 8.3 NEW PRODUCTS LAUNCHES

9. KEY PLAYERS

  • 9.1 PFIZER LIMITED
  • 9.2 BOEHRINGER INGELHEIM
  • 9.3 BAYER AG
  • 9.4 GLAXOSMITHKLINE PLC
  • 9.5 NOVARTIS AG
  • 9.6 F. HOFFMANN-LA ROCHE LTD
  • 9.7 JOHNSON & JOHNSON
  • 9.8 ASTRAZENECA
  • 9.9 CIPLA INC
  • 9.10 MERLION PHARMA
  • 9.11 OTHERS

10. FUTURE OF THE MARKET

Back to Top